Tesamorelin vs Sermorelin — when GHRH analogs aren't interchangeable
7 min read · Uplevel editorial
They're both GHRH analogs. They both work by binding to the growth hormone-releasing hormone receptor on pituitary somatotroph cells and prompting GH secretion. That shared mechanism makes them sound like two versions of the same thing — one perhaps newer, one perhaps stronger — and the choice between them a matter of price or availability or personal preference. That framing misses what actually distinguishes them, which matters enough to get right before a prescribing provider writes anything down.
Sermorelin is a 29-amino-acid peptide corresponding to the first twenty-nine residues of the naturally occurring 44-amino-acid GHRH. It was developed in the 1980s, received FDA approval as Geref for evaluating GH deficiency in children, and was commercially withdrawn for market reasons unrelated to safety. Compounded sermorelin has remained available through licensed compounding pharmacies ever since and continues to be prescribed by providers for adult applications. Its half-life is short — roughly twenty to thirty minutes after subcutaneous injection. GH stimulation peaks and clears relatively quickly, producing a discrete pulse. Because of this, daily dosing is standard, typically at bedtime to align with the natural GH pulse that occurs during the first deep-sleep cycle. The GH and IGF-1 elevation it produces is modest, staying close to physiological range. That modesty is often cited as a feature: the feedback loop remains operative, somatostatin responds appropriately, and the system behaves the way it was designed to behave, with a slight amplification rather than an override.
Tesamorelin is a 44-amino-acid GHRH analog — the full-length GHRH sequence, unlike sermorelin's truncated form — with a trans-3-hexenoic acid modification at the N-terminus that protects it from enzymatic degradation and extends its half-life meaningfully beyond sermorelin's. It received FDA approval in 2010 under the brand name Egrifta for a specific indication: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. That approval rests on randomized controlled trial data showing statistically significant visceral adipose reduction in that population. Its GH and IGF-1 elevation, in clinical studies, is more sustained and somewhat greater in magnitude than what sermorelin typically produces. Daily subcutaneous injection, as with sermorelin — but the effects on visceral adipose that make tesamorelin clinically interesting are not something sermorelin has been studied for in the same way.
The clinical decision between them turns on what the patient needs.
If the primary goal is gentle support of the GH-axis in an adult experiencing the gradual decline of somatopause — improving slow-wave sleep quality, supporting recovery, modest body composition support over months — sermorelin fits that picture well. Its mechanism is well-understood. Its safety profile, after decades of compounded use and several decades of research, is familiar. The subtlety of its effect is appropriate for someone who isn't dealing with severe GH insufficiency but wants to support a system that has been quietly slowing down. The short half-life means it integrates into the normal pulsatile architecture. Bedtime dosing amplifies the sleep-associated GH pulse rather than creating new, pharmacologically forced elevation at other times of day.
If the primary goal is measurable visceral fat reduction — if a patient has clinically significant central adiposity, metabolic syndrome markers, elevated cardiovascular risk from visceral fat, and the prescribing provider has determined that GH-axis intervention is appropriate for this specific situation — tesamorelin has substantially more direct evidence for that outcome. Not for all populations: the FDA approval and the primary evidence base are in HIV lipodystrophy. But the off-label research in non-HIV populations with visceral adiposity, including the NAFLD work, shows a consistent directional signal. Sermorelin has not been studied for visceral fat reduction in any rigorous way; the evidence simply doesn't exist to make a claim about it for that purpose.
The pharmacokinetic difference matters practically too. Sermorelin's short half-life means it produces a pulse and clears. Tesamorelin's stabilized structure means the pituitary stimulus is more sustained after each injection, producing a more prolonged GH secretory response. Whether that sustained stimulation is preferable to sermorelin's shorter pulse depends on the treatment goal. For someone trying to mimic physiological GH pulsatility as closely as possible, sermorelin's brief stimulus may be preferable. For someone targeting visceral fat reduction as a primary metabolic intervention, the more sustained GH stimulation that tesamorelin produces appears to be part of why it works for that purpose.
Cost and access are real factors in this decision and should be discussed honestly. Tesamorelin — brand-name Egrifta — is a pharmaceutical product with a pharmaceutical price: it's expensive when not covered by insurance, and insurance typically covers it only for the approved HIV-lipodystrophy indication. Compounded tesamorelin exists through compounding pharmacies and is substantially less expensive, but the regulatory status of compounded tesamorelin is navigated differently than sermorelin, which has a longer history in the compounding context. Sermorelin, through compounding pharmacies, is generally more accessible and less expensive. A provider prescribing tesamorelin for off-label indications is working in a different access and cost landscape than one prescribing sermorelin for general GH-axis support.
The side-effect profiles differ in degree more than in kind. Both can cause injection site reactions. Both can cause joint discomfort and edema at higher GH levels. Both require glucose monitoring, particularly in anyone with metabolic syndrome or pre-diabetes, because GH elevation opposes insulin action. Tesamorelin's more pronounced GH and IGF-1 elevation — and its studied use in patients with metabolic comorbidities — means the glucose management question is foregrounded in its clinical protocol more explicitly than with sermorelin's gentler effect.
Neither compound is appropriate for active malignancy, uncontrolled hypothyroidism, or pregnancy. Both require baseline labs — including IGF-1 — and ongoing monitoring. Both are prescribed by providers who have reviewed the evidence and the individual patient's context.
The language that probably does the most work here is this: sermorelin is a gentle, long-studied GHRH analog suited to subtle GH-axis support; tesamorelin is a more potent, better-evidenced GHRH analog suited to meaningful visceral-fat-targeted intervention, with a narrower regulatory approval and a more demanding clinical context. They're not interchangeable. The choice between them is the choice between different goals, different evidence bases, and different clinical conversations.
Frequently asked